


PRODUCT INFORMATION



(S)-SLV 319

Item No. 10009022

CAS Registry No.: 464213-10-3
Formal Name: 3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N'-methyl-4S-phenyl-1H-pyrazole-1-carboximidamide
Synonyms: lbipinabant, BMS 646256, JD 5001
MF: C₂₃H₂₀Cl₂N₄O₂S
FW: 487.4
Purity: ≥98%
UV/Vis.: λ_{max}: 228, 314 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

(S)-SLV 319 is supplied as a crystalline solid. A stock solution may be made by dissolving the (S)-SLV 319 in the solvent of choice, which should be purged with an inert gas. (S)-SLV 319 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of (S)-SLV 319 in these solvents is approximately 30 mg/ml.

(S)-SLV 319 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, (S)-SLV 319 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. (S)-SLV 319 has a solubility of approximately 0.25 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Central cannabinoid (CB₁) receptor antagonists may have potential in the treatment of a number of diseases such as neuro-inflammatory disorders, cognitive disorders, septic shock, obesity, psychosis, addiction, and gastrointestinal disorders.¹ (S)-SLV 319 is a potent and selective CB₁ receptor antagonist with K_i values of 7.8 and 7,943 nM for CB₁ and peripheral cannabinoid (CB₂) receptors, respectively.¹ (S)-SLV 319 is less lipophilic (log P = 5.1) and therefore more water soluble than other known CB₁ receptor ligands.²

References

1. Lange, J.H.M., Coolen, H.K.A.C., van Stuivenberg, H.H., *et al.* Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB₁ cannabinoid receptor antagonists. *J. Med. Chem.* **47**(3), 627-643 (2004).
2. Lange, J.H.M., van Stuivenberg, H.H., Veerman, W., *et al.* Novel 3,4-diarylpyrazolines as potent cannabinoid CB₁ receptor antagonists with lower lipophilicity. *Bioorg. Med. Chem. Lett.* **15**(21), 4794-4798 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/01/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM